Aurinia Pharmaceuticals (AUPH) Financials

$8.08 -0.19 (-2.30%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$8.12 +0.04 (+0.56%)

As of 05/23/2025 07:07 PM Eastern

Annual Income Statements for Aurinia Pharmaceuticals

This table shows Aurinia Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016
Net Income / (Loss) Attributable to Common Shareholders	5.75	-78	-108	-181	-103	-88	-54	-71	-23
Consolidated Net Income / (Loss)	5.75	-78	-108	-181	-103	-88	-53	-71	-23
Net Income / (Loss) Continuing Operations	5.75	-78	-108	-181	-103	-88	-54	-71	-23
Total Pre-Tax Income	7.45	-77	-106	-180	-103	-88	-53	-71	-23
Total Operating Income	-4.69	-92	-111	-181	-104	-91	-55	-47	-25
Total Gross Profit	207	161	128	45	50	0.32	0.46	0.42	0.00
Total Revenue	235	176	134	46	50	0.32	0.46	0.42	0.17
Operating Revenue	235	176	134	46	50	0.32	0.46	-	0.01
Total Cost of Revenue	28	14	5.66	1.09	0.00	0.00	0.00	0.00	0.00
Operating Cost of Revenue	28	14	5.66	1.09	0.00	0.00	-	-	0.00
Total Operating Expenses	212	253	240	225	154	91	57	47	25
Selling, General & Admin Expense	172	195	196	174	97	22	14	12	6.97
Research & Development Expense	21	50	45	51	50	53	41	34	15
Other Operating Expenses / (Income)	-4.35	8.38	-1.52	0.57	6.81	15	-0.67	-0.20	2.21
Restructuring Charge	23	0.00	0.00	-	-	-	-	-	-
Total Other Income / (Expense), net	12	14	5.12	0.53	1.52	2.70	2.23	-24	1.73
Interest Expense	4.84	2.78	0.00	0.00	-	-	-	-	-
Interest & Investment Income	17	17	5.12	0.53	1.52	2.70	2.23	-	-
Income Tax Expense	1.70	0.55	1.83	0.76	-0.09	0.14	0.07	-	-
Basic Earnings per Share	$0.04	($0.54)	($0.76)	($1.40)	($0.87)	($0.95)	($0.63)	($0.92)	($0.66)
Weighted Average Basic Shares Outstanding	143.06M	143.24M	141.92M	129.37M	118.47M	93.02M	84.78M	84.05M	-
Diluted Earnings per Share	$0.04	($0.54)	($0.76)	($1.40)	($0.87)	($0.95)	($0.63)	($0.92)	($0.66)
Weighted Average Diluted Shares Outstanding	146.19M	143.24M	141.92M	129.37M	118.47M	93.02M	84.78M	84.05M	-
Weighted Average Basic & Diluted Shares Outstanding	137.34M	144.62M	142.58M	129.37M	118.47M	93.02M	84.78M	84.05M	-

This table shows Aurinia Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	0.96	15	0.72	-11	-27	-13	-12	-26	-26	-8.99
Consolidated Net Income / (Loss)	1.43	14	0.72	-11	-27	-13	-11	-26	-26	-8.99
Net Income / (Loss) Continuing Operations	1.43	14	0.72	-11	-27	-13	-11	-26	-26	-8.99
Total Pre-Tax Income	1.17	15	1.48	-10	-26	-13	-12	-26	-25	-8.04
Total Operating Income	-1.67	12	-1.51	-13	-30	-16	-16	-30	-28	-9.50
Total Gross Profit	54	62	48	43	40	48	40	34	27	53
Total Revenue	60	68	57	50	45	55	41	34	28	56
Operating Revenue	60	68	57	50	45	55	41	34	28	56
Total Cost of Revenue	5.55	6.04	8.91	7.75	5.40	6.77	1.56	0.42	1.36	2.45
Operating Cost of Revenue	5.55	6.04	8.91	7.75	5.40	6.77	1.56	0.42	1.36	2.45
Total Operating Expenses	56	50	50	56	69	64	56	64	55	63
Selling, General & Admin Expense	37	42	45	48	50	48	47	50	47	52
Research & Development Expense	8.11	3.05	4.08	5.55	10	14	13	13	9.87	11
Other Operating Expenses / (Income)	-4.51	4.57	-0.29	-4.13	9.07	2.65	-3.63	0.29	-2.17	-0.31
Restructuring Charge	15	0.00	1.07	6.68	-	0.00	0.00	0.00	-	-
Total Other Income / (Expense), net	2.84	3.06	2.99	3.24	3.26	3.11	4.04	3.81	2.91	1.46
Interest Expense	1.15	1.21	1.20	1.28	1.31	1.40	0.07	0.00	-	0.00
Interest & Investment Income	3.99	4.27	4.19	4.53	4.57	4.51	4.10	3.81	2.91	1.46
Income Tax Expense	-0.26	0.46	0.76	0.74	0.46	0.30	-0.64	0.44	0.86	0.95
Weighted Average Basic Shares Outstanding	143.06M	143.05M	143.33M	144.01M	143.24M	142.85M	142.78M	142.64M	141.92M	141.86M
Weighted Average Diluted Shares Outstanding	146.19M	145.65M	144.11M	144.01M	143.24M	142.85M	142.78M	142.64M	141.92M	141.86M
Weighted Average Basic & Diluted Shares Outstanding	137.34M	143.18M	142.99M	143.02M	144.62M	143.61M	143.42M	143.03M	142.58M	142.11M

This table details how cash moves in and out of Aurinia Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016
Net Change in Cash & Equivalents	35	-45	-138	-40	-34	188	-48	126	44
Net Cash From Operating Activities	44	-33	-80	-158	-70	-64	-52	-41	-21
Net Cash From Continuing Operating Activities	44	-33	-80	-158	-70	-64	-52	-41	-21
Net Income / (Loss) Continuing Operations	5.75	-78	-108	-181	-103	-88	-53	-71	-23
Consolidated Net Income / (Loss)	5.75	-78	-108	-181	-103	-88	-53	-71	-23
Depreciation Expense	19	12	2.71	2.76	1.37	0.03	0.02	0.02	-
Amortization Expense	-13	-12	-1.57	0.66	-	1.14	1.29	-0.12	1.29
Non-Cash Adjustments To Reconcile Net Income	26	51	34	42	21	22	6.15	30	1.25
Changes in Operating Assets and Liabilities, net	5.45	-5.61	-6.82	-22	10	2.03	-6.00	-	-
Net Cash From Investing Activities	39	-6.71	-61	-104	-158	7.78	-0.07	-8.00	31
Net Cash From Continuing Investing Activities	39	-6.71	-61	-104	-158	7.78	-0.07	-8.00	31
Purchase of Property, Plant & Equipment	-0.28	-0.72	-0.29	-1.50	-7.34	-0.09	-0.07	-0.03	-
Purchase of Investments	-546	-524	-524	-445	-203	0.00	-36	-98	-
Sale and/or Maturity of Investments	585	529	464	354	52	7.88	36	90	31
Other Investing Activities, net	-0.04	-12	-0.66	-12	0.00	0.00	-	-	-
Net Cash From Financing Activities	-49	-5.13	2.43	221	194	244	4.01	175	34
Net Cash From Continuing Financing Activities	-49	-5.13	2.43	221	194	244	4.01	166	34
Repurchase of Common Equity	-40	0.00	0.00	-	-	-	-	-	-
Issuance of Common Equity	1.08	1.85	1.91	197	188	223	0.00	162	7.82
Other Financing Activities, net	-9.94	-6.98	0.52	24	6.64	21	4.01	4.14	-
Cash Income Taxes Paid	2.18	0.50	1.98	0.26	0.26	0.06	0.00	-	-

This table details how cash moves in and out of Aurinia Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	46	3.74	-31	16	2.48	-35	-7.29	-5.17	8.12	-66
Net Cash From Operating Activities	30	17	16	-19	14	-13	-2.83	-32	10	-15
Net Cash From Continuing Operating Activities	30	17	16	-19	14	-13	-2.83	-32	10	-15
Net Income / (Loss) Continuing Operations	1.43	14	0.72	-11	-27	-13	-11	-26	-26	-8.99
Consolidated Net Income / (Loss)	1.43	14	0.72	-11	-27	-13	-11	-26	-26	-8.99
Depreciation Expense	4.86	4.89	4.84	4.85	4.95	5.26	0.72	0.72	0.22	1.11
Amortization Expense	-2.98	-3.42	-3.13	-3.21	-3.31	-3.24	-2.99	-2.61	-1.56	-0.67
Non-Cash Adjustments To Reconcile Net Income	4.32	13	7.62	1.27	20	12	8.82	9.68	5.87	9.58
Changes in Operating Assets and Liabilities, net	22	-12	5.78	-11	19	-14	2.12	-13	32	-16
Net Cash From Investing Activities	39	-11	-39	49	-6.26	-20	-5.61	25	-3.02	-50
Net Cash From Continuing Investing Activities	39	-11	-39	49	-6.26	-20	-5.61	25	-3.02	-50
Purchase of Property, Plant & Equipment	-0.28	-	-	0.00	-0.30	0.11	-0.18	-0.35	-0.13	-0.04
Purchase of Investments	-85	-143	-197	-121	-144	-123	-114	-142	-121	-170
Sale and/or Maturity of Investments	124	133	158	171	138	103	121	168	118	120
Other Investing Activities, net	0.00	-	-	-	-	-	-	-	-0.28	-0.38
Net Cash From Financing Activities	-23	-2.72	-8.27	-15	-5.58	-2.33	1.14	1.64	0.69	-
Net Cash From Continuing Financing Activities	-23	-2.72	-8.27	-15	-5.58	-2.33	1.14	1.64	0.69	-
Repurchase of Common Equity	-22	-	-6.13	-12	-	-	-	0.00	-	-
Other Financing Activities, net	-2.33	-2.72	-2.14	-2.75	-7.43	-2.33	1.14	1.64	-1.22	-
Cash Income Taxes Paid	0.73	-	1.46	0.00	0.16	0.06	0.28	0.00	1.20	-

This table presents Aurinia Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016
Total Assets	551	548	471	543	464	324	146	190	57
Total Current Assets	447	425	443	513	419	315	133	175	40
Cash & Equivalents	83	49	94	232	272	306	118	166	40
Short-Term Investments	275	302	295	234	126	0.00	7.89	7.83	0.00
Accounts Receivable	37	24	13	15	0.00	0.37	0.22	0.11	0.09
Inventories, net	39	40	25	19	14	0.00	-	-	-
Prepaid Expenses	11	9.49	14	12	7.17	8.75	6.78	1.68	-
Other Current Assets	1.13	1.03	1.33	0.80	-	-	-	-	-
Plant, Property, & Equipment, net	2.73	3.35	3.65	4.42	4.79	0.09	0.04	0.03	0.00
Total Noncurrent Assets	101	120	25	26	39	9.07	13	15	17
Long-Term Investments	0.00	0.20	0.00	-	24	0.00	-	-	-
Noncurrent Note & Lease Receivables	92	109	0.00	-	-	-	-	-	-
Intangible Assets	4.36	4.98	6.43	8.40	9.33	8.86	13	14	16
Other Noncurrent Operating Assets	4.89	6.02	18	17	5.74	0.21	0.36	0.45	1.71
Total Liabilities & Shareholders' Equity	551	548	471	543	464	324	146	190	57
Total Liabilities	173	170	65	64	56	26	33	24	21
Total Current Liabilities	98	77	46	41	32	11	7.26	8.15	5.79
Accounts Payable	5.19	4.33	40	35	25	11	7.07	7.96	5.79
Accrued Expenses	65	50	-	-	-	-	-	-	-
Current Deferred Revenue	11	4.81	3.15	0.19	-	-	0.12	0.12	-
Other Current Liabilities	17	18	2.97	5.51	7.20	0.12	-	-	-
Total Noncurrent Liabilities	75	93	19	24	24	14	22	12	50
Other Noncurrent Operating Liabilities	75	93	19	24	24	14	-	-	50
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-
Total Equity & Noncontrolling Interests	377	378	405	479	408	299	113	166	0.97
Total Preferred & Common Equity	377	378	405	479	408	299	113	166	0.97
Total Common Equity	377	378	405	479	408	299	113	166	0.97
Common Stock	1,315	1,321	1,271	1,236	984	772	505	499	-
Retained Earnings	-937	-942	-864	-756	-575	-472	-416	-352	-
Accumulated Other Comprehensive Income / (Loss)	-0.65	-0.73	-1.06	-0.85	-0.81	-0.81	-0.81	-0.88	-

This table presents Aurinia Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	549	524	517	555	549	452	488
Total Current Assets	440	410	398	426	416	424	460
Cash & Equivalents	37	33	64	46	82	89	86
Short-Term Investments	312	297	255	292	269	273	291
Accounts Receivable	36	26	29	38	19	19	42
Inventories, net	39	39	40	33	33	32	25
Prepaid Expenses	14	7.84	7.65	16	11	10	12
Other Current Assets	2.70	6.98	2.00	1.65	1.21	1.23	3.81
Plant, Property, & Equipment, net	2.89	3.04	3.20	3.50	3.65	3.84	3.76
Total Noncurrent Assets	106	111	115	125	129	24	25
Long-Term Investments	0.00	0.20	0.20	0.59	-	-	-
Intangible Assets	4.51	4.62	4.76	5.26	5.68	6.10	6.84
Other Noncurrent Operating Assets	102	5.16	5.90	6.13	6.23	18	18
Total Liabilities & Shareholders' Equity	549	524	517	555	549	452	488
Total Liabilities	161	159	157	163	157	61	65
Total Current Liabilities	79	77	71	74	62	42	42
Accounts Payable	57	56	50	52	41	36	40
Current Deferred Revenue	4.30	4.37	4.91	4.66	3.23	3.16	-
Other Current Liabilities	18	16	16	17	17	2.92	1.64
Total Noncurrent Liabilities	83	82	86	89	95	19	23
Other Noncurrent Operating Liabilities	83	82	86	89	95	19	23
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	388	365	359	392	392	390	423
Total Preferred & Common Equity	388	365	359	392	392	390	423
Total Common Equity	388	365	359	392	392	390	423
Common Stock	1,326	1,318	1,313	1,308	1,295	1,282	1,263
Retained Earnings	-938	-952	-953	-915	-902	-891	-838
Accumulated Other Comprehensive Income / (Loss)	-0.39	-0.86	-0.85	-0.95	-1.02	-0.99	-1.53

This table displays calculated financial ratios and metrics derived from Aurinia Pharmaceuticals' official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016
Growth Metrics	-	-	-	-	-	-	-	-	-
Revenue Growth	33.97%	30.95%	193.89%	-9.00%	15,660.38%	-31.32%	10.77%	141.62%	0.00%
EBITDA Growth	102.20%	16.45%	37.77%	-72.29%	-14.64%	-66.47%	23.93%	-222.13%	0.00%
EBIT Growth	94.89%	17.74%	38.32%	-73.30%	-14.68%	-64.63%	21.97%	-203.89%	0.00%
NOPAT Growth	94.36%	17.74%	38.32%	-73.30%	-14.68%	-64.63%	-17.86%	-87.27%	0.00%
Net Income Growth	107.37%	27.88%	40.22%	-76.24%	-16.17%	-66.52%	25.02%	-203.89%	0.00%
EPS Growth	107.41%	28.95%	45.71%	-60.92%	8.42%	-50.79%	31.52%	-39.39%	0.00%
Operating Cash Flow Growth	232.66%	57.93%	49.57%	-125.73%	-9.87%	-23.20%	-25.36%	-98.33%	0.00%
Free Cash Flow Firm Growth	106.16%	6.98%	47.53%	-135.99%	-49.64%	-1.04%	45.44%	0.00%	0.00%
Invested Capital Growth	-30.30%	69.92%	23.30%	186.99%	-101.63%	-159.38%	58.84%	120.34%	0.00%
Revenue Q/Q Growth	6.70%	10.49%	3.90%	-36.86%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	107.73%	1.51%	2.23%	-16.09%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Q/Q Growth	85.66%	-1.75%	3.97%	-15.79%	0.00%	0.00%	0.00%	0.00%	0.00%
NOPAT Q/Q Growth	84.18%	-1.75%	3.97%	-15.79%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Income Q/Q Growth	125.51%	-1.07%	6.30%	-16.21%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS Q/Q Growth	126.67%	-1.89%	7.32%	-14.75%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	55.28%	10.35%	31.38%	-22.65%	0.00%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	153.03%	-8.20%	30.28%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	-51.59%	-48.93%	-65.70%	10.54%	0.00%	0.00%	0.00%	0.00%	0.00%
Profitability Metrics	-	-	-	-	-	-	-	-	-
Gross Margin	87.99%	91.94%	95.77%	97.61%	100.00%	100.00%	100.00%	100.00%	0.58%
EBITDA Margin	0.86%	-52.52%	-82.32%	-388.80%	-205.35%	-28,230.19%	-11,647.30%	-16,958.85%	-12,720.23%
Operating Margin	-1.99%	-52.24%	-83.17%	-396.31%	-208.09%	-28,598.43%	-11,930.89%	-11,212.44%	-14,466.47%
EBIT Margin	-1.99%	-52.24%	-83.17%	-396.31%	-208.09%	-28,598.43%	-11,930.89%	-16,935.89%	-13,465.32%
Profit (Net Income) Margin	2.45%	-44.45%	-80.71%	-396.81%	-204.88%	-27,794.03%	-11,464.15%	-16,935.89%	-13,465.32%
Tax Burden Percent	77.23%	100.71%	101.72%	100.42%	99.91%	100.16%	100.14%	100.00%	100.00%
Interest Burden Percent	-158.91%	84.49%	95.41%	99.71%	98.55%	97.03%	95.96%	100.00%	100.00%
Effective Tax Rate	22.77%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-15.65%	-296.40%	-537.06%	0.00%	0.00%	-2,508.77%	-379.84%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-18.29%	-292.66%	-530.01%	0.00%	0.00%	-2,496.60%	-368.67%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	17.17%	276.48%	512.60%	0.00%	0.00%	2,465.78%	341.70%	0.00%	0.00%
Return on Equity (ROE)	1.52%	-19.92%	-24.46%	-40.81%	-29.07%	-42.99%	-38.14%	-84.93%	-2,399.07%
Cash Return on Invested Capital (CROIC)	20.07%	-348.21%	-557.93%	-1,187.17%	0.00%	0.00%	-425.30%	-1,008.79%	0.00%
Operating Return on Assets (OROA)	-0.85%	-18.00%	-21.98%	-35.89%	-26.47%	-38.69%	-32.91%	-57.36%	-40.87%
Return on Assets (ROA)	1.05%	-15.31%	-21.33%	-35.94%	-26.06%	-37.60%	-31.62%	-57.36%	-40.87%
Return on Common Equity (ROCE)	1.52%	-19.92%	-24.46%	-40.81%	-29.07%	-42.99%	-38.14%	-84.93%	-2,399.07%
Return on Equity Simple (ROE_SIMPLE)	1.52%	-20.64%	-26.68%	-37.77%	-25.18%	-29.60%	-47.15%	-42.71%	-2,399.07%
Net Operating Profit after Tax (NOPAT)	-3.62	-64	-78	-127	-73	-64	-39	-33	-18
NOPAT Margin	-1.54%	-36.57%	-58.22%	-277.41%	-145.66%	-20,018.90%	-8,351.62%	-7,848.71%	-10,126.53%
Net Nonoperating Expense Percent (NNEP)	2.64%	-3.74%	-7.05%	-12.25%	-8.14%	-12.18%	-11.17%	-38.46%	-14.57%
Return On Investment Capital (ROIC_SIMPLE)	-0.96%	-16.98%	-19.25%	-	-	-	-	-	-
Cost of Revenue to Revenue	12.01%	8.06%	4.23%	2.39%	0.00%	0.00%	0.00%	0.00%	2.31%
SG&A Expenses to Revenue	73.16%	111.12%	146.51%	380.52%	194.09%	7,024.53%	2,957.67%	2,893.78%	4,028.90%
R&D to Revenue	8.84%	28.28%	33.57%	112.13%	100.42%	16,624.53%	8,937.80%	8,117.22%	8,401.16%
Operating Expenses to Revenue	89.98%	144.18%	178.94%	493.91%	308.09%	28,698.43%	12,318.57%	11,312.44%	14,564.16%
Earnings before Interest and Taxes (EBIT)	-4.69	-92	-111	-181	-104	-91	-55	-71	-23
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	2.03	-92	-110	-177	-103	-90	-54	-71	-22
Valuation Ratios	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.41	3.42	1.51	6.19	3.79	5.80	5.09	0.00	0.00
Price to Tangible Book Value (P/TBV)	3.45	3.46	1.54	6.30	3.88	5.98	5.73	0.00	0.00
Price to Revenue (P/Rev)	5.47	7.36	4.58	65.03	30.85	5,447.28	1,238.08	0.00	0.00
Price to Earnings (P/E)	223.53	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.45%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	48.80	34.49	13.99	192.08	0.00	0.00	37.55	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	3.94	5.36	1.68	54.81	22.42	4,484.95	1,013.23	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	457.46	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	20.89	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	199.75	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.19	0.07	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.19	0.07	0.00
Financial Leverage	-0.94	-0.94	-0.97	-1.00	-1.03	-0.99	-0.93	-1.18	-40.83
Leverage Ratio	1.45	1.30	1.15	1.14	1.12	1.14	1.21	1.48	58.70
Compound Leverage Factor	-2.31	1.10	1.09	1.13	1.10	1.11	1.16	1.48	58.70
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	16.19%	6.64%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	16.19%	6.64%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	83.81%	93.36%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	-0.40	-0.17	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	1.93	2.28	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	-0.40	-0.17	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	-0.56	-0.36	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	2.69	4.93	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	-0.56	-0.36	0.00
Altman Z-Score	3.23	2.68	3.57	25.76	15.22	38.60	6.13	0.00	0.00
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-
Current Ratio	4.57	5.50	9.60	12.63	13.11	27.90	18.30	21.50	6.86
Quick Ratio	4.04	4.85	8.74	11.85	12.45	27.13	17.36	21.30	6.86
Cash Flow Metrics	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	4.64	-75	-81	-154	-65	-44	-43	-79	0.00
Operating Cash Flow to CapEx	15,796.44%	-4,660.31%	-27,235.96%	-10,505.80%	-951.36%	-74,805.88%	-69,744.59%	-164,676.00%	0.00%
Free Cash Flow to Firm to Interest Expense	0.96	-27.17	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	9.18	-12.06	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	9.12	-12.32	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-
Asset Turnover	0.43	0.34	0.26	0.09	0.13	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	7.76	9.34	9.28	0.00	0.00	1.09	2.84	4.29	2.01
Inventory Turnover	0.72	0.44	0.26	0.07	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	77.28	50.12	33.23	9.91	20.54	4.75	12.86	0.00	0.00
Accounts Payable Turnover	5.94	0.64	0.15	0.04	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	47.06	39.07	39.35	0.00	0.00	335.73	128.50	85.14	181.45
Days Inventory Outstanding (DIO)	509.96	831.45	1,420.24	5,562.49	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	61.47	571.66	2,414.55	9,993.84	0.00	0.00	0.00	0.00	528,428.75
Cash Conversion Cycle (CCC)	495.55	298.86	-954.96	-4,431.35	0.00	335.73	128.50	85.14	-528,247.30
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-
Invested Capital	19	27	16	13	-15	-7.42	12	7.87	-39
Invested Capital Turnover	10.16	8.11	9.23	-46.87	-4.48	0.13	0.05	-0.03	0.00
Increase / (Decrease) in Invested Capital	-8.26	11	3.03	28	-7.54	-20	4.63	47	0.00
Enterprise Value (EV)	927	940	225	2,499	1,123	1,426	469	0.00	0.00
Market Capitalization	1,286	1,291	614	2,966	1,546	1,732	573	0.00	0.00
Book Value per Share	$2.64	$2.63	$2.85	$3.69	$3.65	$3.49	$1.34	$1.97	$0.00
Tangible Book Value per Share	$2.61	$2.60	$2.81	$3.63	$3.56	$3.39	$1.19	$1.80	$0.00
Total Capital	377	378	405	479	408	299	134	178	0.97
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	22	12	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	22	12	0.00
Net Debt	-358	-351	-389	-466	-423	-306	-104	-162	-40
Capital Expenditures (CapEx)	0.28	0.72	0.29	1.50	7.34	0.09	0.07	0.03	-0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-9.64	-2.88	7.04	6.60	-11	-2.18	-0.27	-6.36	-5.71
Debt-free Net Working Capital (DFNWC)	349	348	396	473	387	304	126	167	34
Net Working Capital (NWC)	349	348	396	473	387	304	126	167	34
Net Nonoperating Expense (NNE)	-9.37	14	30	54	30	25	14	38	5.78
Net Nonoperating Obligations (NNO)	-358	-351	-389	-466	-423	-306	-100	-158	-40
Total Depreciation and Amortization (D&A)	6.71	-0.49	1.13	3.42	1.37	1.17	1.31	-0.10	1.29
Debt-free, Cash-free Net Working Capital to Revenue	-4.10%	-1.64%	5.25%	14.47%	-21.75%	-684.59%	-58.10%	-1,521.53%	-3,297.69%
Debt-free Net Working Capital to Revenue	148.36%	198.05%	295.78%	1,036.46%	773.04%	95,547.80%	27,124.62%	39,976.56%	19,620.81%
Net Working Capital to Revenue	148.36%	198.05%	295.78%	1,036.46%	773.04%	95,547.80%	27,124.62%	39,976.56%	19,620.81%
Earnings Adjustments	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.04	($0.54)	($0.76)	($1.40)	($0.87)	$0.00	($0.76)	($0.92)	$0.00
Adjusted Weighted Average Basic Shares Outstanding	143.06M	143.24M	141.92M	141.65M	127.45M	111.80M	85.50M	84.05M	0.00
Adjusted Diluted Earnings per Share	$0.04	($0.54)	($0.76)	($1.40)	($0.87)	$0.00	($0.76)	($0.92)	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	146.19M	143.24M	141.92M	141.65M	127.45M	111.80M	85.50M	84.05M	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	($0.87)	$0.00	($0.76)	($0.92)	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	137.34M	144.62M	142.58M	129.37M	118.47M	111.80M	85.50M	84.05M	0.00
Normalized Net Operating Profit after Tax (NOPAT)	14	-64	-78	-127	-73	-64	-39	-33	-18
Normalized NOPAT Margin	6.05%	-36.57%	-58.22%	-277.41%	-145.66%	-20,018.90%	-8,351.62%	-7,848.71%	-10,126.53%
Pre Tax Income Margin	3.17%	-44.14%	-79.35%	-395.15%	-205.06%	-27,748.74%	-11,448.38%	-16,935.89%	-13,465.32%
Debt Service Ratios	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-0.97	-33.04	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	-0.75	-23.13	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	-1.03	-33.30	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	-0.81	-23.39	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	699.57%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Aurinia Pharmaceuticals' official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	32.76%	24.32%	37.83%	46.19%	58.59%	-2.27%	47.19%	59.12%	21.50%	280.30%
EBITDA Growth	100.76%	192.85%	101.11%	63.11%	4.79%	-57.24%	47.22%	14.70%	7.93%	81.74%
EBIT Growth	94.38%	172.24%	90.64%	55.20%	-5.60%	-71.21%	55.07%	21.90%	14.08%	81.14%
NOPAT Growth	90.21%	200.01%	93.47%	55.20%	-5.60%	-71.21%	55.07%	21.90%	14.08%	81.14%
Net Income Growth	105.32%	206.72%	106.28%	58.98%	-3.18%	-49.59%	67.64%	30.36%	21.84%	82.11%
EPS Growth	0.00%	211.11%	112.50%	61.11%	-5.56%	-50.00%	68.00%	33.33%	25.00%	84.62%
Operating Cash Flow Growth	110.41%	228.26%	660.62%	41.28%	36.96%	13.57%	89.86%	32.25%	140.31%	61.83%
Free Cash Flow Firm Growth	119.47%	241.84%	133.06%	2.20%	-40.92%	56.82%	57.16%	56.55%	55.37%	11.40%
Invested Capital Growth	-30.30%	-26.47%	-18.37%	36.33%	69.92%	14.12%	29.80%	-1.69%	23.30%	297.39%
Revenue Q/Q Growth	-11.66%	18.50%	13.70%	11.55%	-17.28%	31.38%	20.59%	21.01%	-49.02%	97.86%
EBITDA Q/Q Growth	-98.38%	6,348.78%	101.77%	58.57%	-96.87%	22.78%	41.42%	-6.93%	-225.11%	74.08%
EBIT Q/Q Growth	-114.21%	876.47%	88.58%	55.34%	-82.46%	-0.58%	45.34%	-5.28%	-195.82%	73.61%
NOPAT Q/Q Growth	-117.86%	1,640.45%	92.03%	55.34%	-82.46%	-0.58%	45.34%	-5.28%	-195.82%	73.61%
Net Income Q/Q Growth	-90.04%	1,887.53%	106.72%	60.00%	-99.86%	-17.01%	56.15%	-0.61%	-189.75%	74.69%
EPS Q/Q Growth	0.00%	900.00%	114.29%	63.16%	-111.11%	-12.50%	55.56%	0.00%	-200.00%	76.00%
Operating Cash Flow Q/Q Growth	76.84%	7.49%	185.19%	-229.95%	207.80%	-369.82%	91.08%	-403.06%	168.03%	44.88%
Free Cash Flow Firm Q/Q Growth	-75.59%	269.92%	134.89%	38.21%	-77.83%	13.79%	-3.24%	10.97%	45.50%	14.47%
Invested Capital Q/Q Growth	-51.59%	15.65%	-13.78%	44.38%	-48.93%	28.40%	44.00%	79.96%	-65.70%	46.04%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	90.73%	91.10%	84.42%	84.59%	88.04%	87.58%	96.23%	98.78%	95.21%	95.61%
EBITDA Margin	0.36%	19.51%	0.36%	-23.08%	-62.16%	-26.12%	-44.44%	-91.48%	-103.53%	-16.23%
Operating Margin	-2.79%	17.33%	-2.65%	-26.35%	-65.80%	-29.83%	-38.97%	-85.98%	-98.82%	-17.03%
EBIT Margin	-2.79%	17.33%	-2.65%	-26.35%	-65.80%	-29.83%	-38.97%	-85.98%	-98.82%	-17.03%
Profit (Net Income) Margin	2.39%	21.17%	1.26%	-21.37%	-59.60%	-24.67%	-27.70%	-76.16%	-91.60%	-16.12%
Tax Burden Percent	121.82%	96.91%	48.85%	107.38%	101.74%	102.27%	94.71%	101.69%	103.39%	111.87%
Interest Burden Percent	-70.28%	126.04%	-97.69%	75.53%	89.02%	80.85%	75.04%	87.11%	89.65%	84.59%
Effective Tax Rate	-21.82%	3.09%	51.15%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-34.52%	79.92%	-7.09%	-103.46%	-373.34%	-66.23%	-118.67%	-303.40%	-638.14%	-52.53%
ROIC Less NNEP Spread (ROIC-NNEP)	-35.50%	79.06%	-7.52%	-103.03%	-371.69%	-65.66%	-118.63%	-302.00%	-636.65%	-51.82%
Return on Net Nonoperating Assets (RNNOA)	33.32%	-69.67%	6.77%	93.65%	351.14%	57.59%	107.92%	281.02%	615.74%	47.62%
Return on Equity (ROE)	-1.20%	10.25%	-0.32%	-9.81%	-22.20%	-8.64%	-10.75%	-22.39%	-22.41%	-4.91%
Cash Return on Invested Capital (CROIC)	20.07%	-18.90%	-92.31%	-185.36%	-348.21%	-139.14%	-184.47%	-246.28%	-557.93%	-397.12%
Operating Return on Assets (OROA)	-1.19%	6.92%	-1.02%	-10.41%	-22.67%	-9.08%	-12.10%	-26.33%	-26.12%	-5.18%
Return on Assets (ROA)	1.02%	8.45%	0.49%	-8.45%	-20.53%	-7.51%	-8.60%	-23.33%	-24.21%	-4.90%
Return on Common Equity (ROCE)	-1.20%	10.25%	-0.32%	-9.81%	-22.20%	-8.64%	-10.75%	-22.39%	-22.41%	-4.91%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-5.81%	-13.81%	-17.40%	0.00%	-19.70%	-18.54%	-24.78%	0.00%	-27.27%
Net Operating Profit after Tax (NOPAT)	-2.03	11	-0.74	-9.28	-21	-11	-11	-21	-20	-6.65
NOPAT Margin	-3.40%	16.80%	-1.29%	-18.44%	-46.06%	-20.88%	-27.28%	-60.18%	-69.18%	-11.92%
Net Nonoperating Expense Percent (NNEP)	0.98%	0.86%	0.43%	-0.43%	-1.65%	-0.58%	-0.05%	-1.41%	-1.49%	-0.71%
Return On Investment Capital (ROIC_SIMPLE)	-0.54%	-	-	-	-5.50%	-	-	-	-4.85%	-
Cost of Revenue to Revenue	9.27%	8.91%	15.58%	15.41%	11.96%	12.42%	3.77%	1.22%	4.79%	4.39%
SG&A Expenses to Revenue	61.86%	62.51%	78.57%	94.82%	111.04%	87.61%	113.46%	145.67%	166.95%	93.53%
R&D to Revenue	13.54%	4.50%	7.13%	11.04%	22.68%	24.96%	30.49%	38.24%	34.71%	19.67%
Operating Expenses to Revenue	93.51%	73.76%	87.07%	110.94%	153.84%	117.42%	135.20%	184.75%	194.03%	112.64%
Earnings before Interest and Taxes (EBIT)	-1.67	12	-1.51	-13	-30	-16	-16	-30	-28	-9.50
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	0.21	13	0.21	-12	-28	-14	-18	-31	-29	-9.06
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.41	2.70	2.24	2.00	3.42	2.84	3.53	4.00	1.51	2.52
Price to Tangible Book Value (P/TBV)	3.45	2.73	2.27	2.03	3.46	2.88	3.58	4.07	1.54	2.56
Price to Revenue (P/Rev)	5.47	4.76	3.94	3.76	7.36	7.02	8.65	10.64	4.58	8.27
Price to Earnings (P/E)	223.53	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.45%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	48.80	17.82	14.32	10.15	34.49	14.53	24.86	41.60	13.99	14.76
Enterprise Value to Revenue (EV/Rev)	3.94	3.17	2.35	2.09	5.36	4.88	6.46	8.18	1.68	5.35
Enterprise Value to EBITDA (EV/EBITDA)	457.46	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	20.89	24.47	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	199.75	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.94	-0.88	-0.90	-0.91	-0.94	-0.88	-0.91	-0.93	-0.97	-0.92
Leverage Ratio	1.45	1.42	1.42	1.29	1.30	1.28	1.26	1.14	1.15	1.18
Compound Leverage Factor	-1.02	1.78	-1.38	0.98	1.16	1.03	0.95	1.00	1.03	0.99
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	3.25	2.77	1.69	1.21	3.05	2.74	3.97	13.64	4.16	8.69
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.57	5.60	5.33	5.60	5.50	5.77	6.75	10.08	9.60	11.01
Quick Ratio	4.04	4.90	4.63	4.91	4.85	5.09	6.00	9.05	8.74	10.02
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	6.23	26	6.90	-20	-32	-18	-21	-20	-23	-42
Operating Cash Flow to CapEx	10,716.73%	0.00%	0.00%	0.00%	4,786.62%	0.00%	-1,596.61%	-9,126.80%	7,798.51%	-38,405.00%
Free Cash Flow to Firm to Interest Expense	5.44	21.12	5.76	-15.41	-24.42	-12.85	-321.02	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	26.28	14.10	13.22	-14.50	10.93	-9.48	-43.48	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	26.03	14.10	13.22	-14.50	10.70	-9.41	-46.20	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.43	0.40	0.39	0.40	0.34	0.30	0.31	0.31	0.26	0.30
Accounts Receivable Turnover	7.76	5.92	9.20	7.98	9.34	3.99	8.50	7.44	9.28	5.00
Inventory Turnover	0.72	0.79	0.80	0.60	0.44	0.35	0.20	0.20	0.26	0.21
Fixed Asset Turnover	77.28	69.05	61.89	54.38	50.12	43.80	40.88	35.92	33.23	31.05
Accounts Payable Turnover	5.94	0.52	0.59	0.50	0.64	0.22	0.16	0.17	0.15	0.14
Days Sales Outstanding (DSO)	47.06	61.64	39.67	45.72	39.07	91.58	42.94	49.04	39.35	72.98
Days Inventory Outstanding (DIO)	509.96	464.74	455.90	607.56	831.45	1,048.99	1,859.28	1,816.26	1,420.24	1,702.25
Days Payable Outstanding (DPO)	61.47	708.66	619.42	732.71	571.66	1,667.71	2,323.54	2,138.15	2,414.55	2,674.47
Cash Conversion Cycle (CCC)	495.55	-182.28	-123.85	-79.42	298.86	-527.13	-421.33	-272.85	-954.96	-899.23
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	19	39	34	39	27	53	42	29	16	47
Invested Capital Turnover	10.16	4.76	5.48	5.61	8.11	3.17	4.35	5.04	9.23	4.41
Increase / (Decrease) in Invested Capital	-8.26	-14	-7.64	10	11	6.61	9.55	-0.50	3.03	35
Enterprise Value (EV)	927	699	486	399	940	776	1,034	1,201	225	690
Market Capitalization	1,286	1,048	817	719	1,291	1,114	1,385	1,563	614	1,067
Book Value per Share	$2.64	$2.71	$2.55	$2.50	$2.63	$2.73	$2.74	$2.74	$2.85	$2.98
Tangible Book Value per Share	$2.61	$2.68	$2.52	$2.46	$2.60	$2.70	$2.70	$2.70	$2.81	$2.94
Total Capital	377	388	365	359	378	392	392	390	405	423
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-358	-349	-331	-320	-351	-338	-351	-362	-389	-377
Capital Expenditures (CapEx)	0.28	0.00	0.00	0.00	0.30	-0.11	0.18	0.35	0.13	0.04
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-9.64	13	2.29	7.26	-2.88	15	3.53	20	7.04	41
Debt-free Net Working Capital (DFNWC)	349	362	333	327	348	353	354	382	396	418
Net Working Capital (NWC)	349	362	333	327	348	353	354	382	396	418
Net Nonoperating Expense (NNE)	-3.46	-2.96	-1.46	1.47	6.10	2.06	0.17	5.50	6.38	2.34
Net Nonoperating Obligations (NNO)	-358	-349	-331	-320	-351	-338	-351	-362	-389	-377
Total Depreciation and Amortization (D&A)	1.88	1.47	1.72	1.64	1.64	2.03	-2.27	-1.89	-1.34	0.44
Debt-free, Cash-free Net Working Capital to Revenue	-4.10%	5.95%	1.10%	3.79%	-1.64%	9.24%	2.21%	13.67%	5.25%	32.01%
Debt-free Net Working Capital to Revenue	148.36%	164.21%	160.67%	170.93%	198.05%	221.95%	221.24%	259.92%	295.78%	323.98%
Net Working Capital to Revenue	148.36%	164.21%	160.67%	170.93%	198.05%	221.95%	221.24%	259.92%	295.78%	323.98%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.10	$0.01	($0.07)	($0.19)	($0.09)	($0.08)	($0.18)	($0.18)	($0.06)
Adjusted Weighted Average Basic Shares Outstanding	143.06M	143.05M	143.33M	144.01M	143.24M	142.85M	142.78M	142.64M	141.92M	141.86M
Adjusted Diluted Earnings per Share	$0.00	$0.10	$0.01	($0.07)	($0.19)	($0.09)	($0.08)	($0.18)	($0.18)	($0.06)
Adjusted Weighted Average Diluted Shares Outstanding	146.19M	145.65M	144.11M	144.01M	143.24M	142.85M	142.78M	142.64M	141.92M	141.86M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	137.34M	143.18M	142.99M	143.02M	144.62M	143.61M	143.42M	143.03M	142.58M	142.11M
Normalized Net Operating Profit after Tax (NOPAT)	9.58	11	-0.31	-4.60	-21	-11	-11	-21	-20	-6.65
Normalized NOPAT Margin	16.00%	16.80%	-0.54%	-9.14%	-46.06%	-20.88%	-27.28%	-60.18%	-69.18%	-11.92%
Pre Tax Income Margin	1.96%	21.85%	2.58%	-19.90%	-58.58%	-24.12%	-29.24%	-74.89%	-88.59%	-14.41%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-1.46	9.73	-1.26	-10.33	-22.65	-11.62	-248.77	0.00	0.00	0.00
NOPAT to Interest Expense	-1.77	9.43	-0.62	-7.23	-15.86	-8.13	-174.14	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	-1.70	9.73	-1.26	-10.33	-22.88	-11.54	-251.49	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	-2.02	9.43	-0.62	-7.23	-16.08	-8.06	-176.86	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	699.57%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Aurinia Pharmaceuticals' Financials

When does Aurinia Pharmaceuticals's fiscal year end?

According to the most recent income statement we have on file, Aurinia Pharmaceuticals' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Aurinia Pharmaceuticals' net income changed over the last 8 years?

Aurinia Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of $5.75 million in 2024, falling from -$23.30 million in 2016. The previous period was -$78.02 million in 2023. Find out what analysts predict for Aurinia Pharmaceuticals in the coming months.

What is Aurinia Pharmaceuticals's operating income?

Aurinia Pharmaceuticals's total operating income in 2024 was -$4.69 million, based on the following breakdown:

Total Gross Profit: $206.89 million
Total Operating Expenses: $211.57 million

How has Aurinia Pharmaceuticals revenue changed over the last 8 years?

Over the last 8 years, Aurinia Pharmaceuticals' total revenue changed from $173 thousand in 2016 to $235.13 million in 2024, a change of 135,815.0%.

How much debt does Aurinia Pharmaceuticals have?

Aurinia Pharmaceuticals' total liabilities were at $173.17 million at the end of 2024, a 1.8% increase from 2023, and a 722.8% increase since 2016.

How much cash does Aurinia Pharmaceuticals have?

In the past 8 years, Aurinia Pharmaceuticals' cash and equivalents has ranged from $39.65 million in 2016 to $306.02 million in 2019, and is currently $83.43 million as of their latest financial filing in 2024.

How has Aurinia Pharmaceuticals' book value per share changed over the last 8 years?

Over the last 8 years, Aurinia Pharmaceuticals' book value per share changed from 0.00 in 2016 to 2.64 in 2024, a change of 263.6%.

Related Companies

This page (NASDAQ:AUPH) was last updated on 5/25/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aurinia Pharmaceuticals (AUPH) Financials

Frequently Asked Questions About Aurinia Pharmaceuticals' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aurinia Pharmaceuticals (AUPH) Financials

Annual Income Statements for Aurinia Pharmaceuticals

Quarterly Income Statements for Aurinia Pharmaceuticals

Annual Cash Flow Statements for Aurinia Pharmaceuticals

Quarterly Cash Flow Statements for Aurinia Pharmaceuticals

Annual Balance Sheets for Aurinia Pharmaceuticals

Quarterly Balance Sheets for Aurinia Pharmaceuticals

Annual Metrics And Ratios for Aurinia Pharmaceuticals

Quarterly Metrics And Ratios for Aurinia Pharmaceuticals

Frequently Asked Questions About Aurinia Pharmaceuticals' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools